



ASX:EXL | OTCQB:ELLXF

Investor Presentation

April 2021



Kind of Amazing

Disclaimer

This presentation contains summary information about Elixinol Global Limited (Elixinol) and its subsidiaries and their activities.

The information in this presentation does not purport to be complete. It should be read in conjunction with Elixinol's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

The information contained in this presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek independent professional advice appropriate to their jurisdiction and circumstances.

To the maximum extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by Elixinol, any of its related bodies corporate or its directors, officers, employees, professional advisers and agents (Related Parties). No representation or warranty, express or implied, is made by any person, including Elixinol and its Related Parties, as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

An investment in Elixinol securities is subject to investment and other known and unknown risks, some of which are beyond the control of Elixinol or its directors. Elixinol does not guarantee any particular rate of return or the performance of Elixinol securities.

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of Elixinol and associated entities of Elixinol and certain plans and objectives of the management of Elixinol. Forward-looking statements can be identified by the use of forward-looking terminology, including, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may" or "will", and similar expressions. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of Elixinol to be materially different from the results or performance expressed or implied by such forward-looking statements.


Such forward-looking statements are based on numerous assumptions regarding Elixinol's present and future business strategies and the political, regulatory and economic environment in which Elixinol will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved. Forward-looking statements speak only as at the date of this presentation and to the maximum extent permitted by law, Elixinol and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, any assumptions or expectations set out in this presentation).

All figures in this presentation are A\$ unless stated otherwise and all market shares are estimates only. A number of figures, amounts, percentages, estimates, calculations of value and fractions are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this presentation.

Elixinol CBD



elixinolSkin CBD



Hemp Foods Australia



Our Vision

Building a global, hemp derived, health and wellness consumer products business.

Our Mission

Making a positive contribution to people's health, wellness and the planet through the power of hemp products.



Quality & transparency



Heritage



Compliance focus



Rejuvenated Leadership

To facilitate the turn-around, new leadership capabilities have been put in place at all levels. Specific focus given to augmenting strategic, commercial and governance disciplines.



Chair - Helen Wiseman

Non-executive director and audit committee specialist with extensive international experience in food, pharmaceutical, natural healthcare, professional services, energy and natural resources and manufacturing industries. As a former partner of KPMG and previously named as one of the 2014 Australian Financial Review and Westpac 100 Women of Influence, she brings diversity and seasoned governance skills to the board.



Global CEO and Executive Director – Oliver Horn

Most recently CEO of Swisse Wellness for Australia and New Zealand (ANZ) and North America. With an established track record for exponential growth in established and emerging markets, Oliver has extensive experience in building premium global consumer brands, a deep knowledge of the vitamins, minerals and supplements (VMS) category, a track record of premium brand building and a passion for creating businesses with a positive and thriving workplace culture.



Global CFO – Ron Dufficy

Ron is a senior finance executive having held various leadership roles with ASX-listed companies such as CSR Ltd (ASX: CSR) and Aristocrat Leisure Ltd (ASX: ALL). Ron has significant experience in regulated markets including being based in the USA for 9 years, most recently as CFO for Aristocrat's largest and most profitable division, responsible for developing and implementing strategies to improve profit margins, grow market share and creating a global shared services organisation.

An expanding global footprint

Our global footprint gives us access to high growth markets and diversifies risk.

AMERICAS (56% of Group Revenues) (2020 US\$5b > 2025 US\$17b, CAGR of +26% *)

- **Est. 2014. One of most trusted brands (*CBD insider)**
- Colorado HQ. 37 FTE managing sales, marketing, production and logistics
- Growth focus:
 - E-commerce
 - NPD
 - Wellness Channel
- Exports into Latin America



Mexico

Europe (16% of Group Revenues) (2020 US\$554m > 2025 US\$2.3b, CAGR of +34% *)

- **Est. 2018. #1 mover advantage**
- UK & NL entities with dispersed team of 10 FTE managing sales, marketing & distribution
- Fully outsourced supply chain
- Growth focus on UK & GER:
 - Pharmacy
 - E-commerce
 - TV shopping
- Long-term distribution arrangement with South Africa



South Africa

Japan

- **Most established and leading brand in Japan**
- Licensing agreement with Elixinol Japan, supply of HFA products
- HFA testing route to market into China cross border E-Commerce
- Growth focus:
 - Invest in Japan
 - Monitor SEA

Australia (28% of Group Revenues)


- **Est. 1999. Leading hemp foods brand**
- Sydney based Global HQ with 5 FTE
- HFA Byron Bay Office with 10 FTE managing production, sales & marketing of finished goods & bulk, exports to South Africa and Japan
- >1,200 distribution points
- Growth focus:
 - CBD in Australia
 - HFA hemp foods through NPD & E-Com



Global CBD market outlook & regulations

The global CBD industry is still in its early stages of consumer adoption. Regulations are changing fast and in favour of CBD.


US CBD Market Size & Forecast (2019-2025)



US CBD market¹:

- US\$4.2B in 2019 expected to grow to US\$16.8B by 2025
- Forecast growth 2020-2025 CAGR of 26%

European CBD Market Size & Forecast (2020-2025)



European CBD market²:

- US\$0.6B in 2020 expected to grow to US\$2.3B by 2025
- Forecast growth 2020-2025 CAGR of 34%

Regulation differs across key markets

The UN accepts WHO's recognising the medicinal value of cannabis moving it to schedule 1

US regulatory framework uncertain:

- Market remains fragmented and highly competitive, but cannabis reform continues to build momentum under Democratic government. Congress passes SAFE Banking Act on 20th April. It is widely expected that the FDA will regulate CBD as a dietary supplement within 24 months.

Europe now has the most stable and positive regulatory environment:

- The **EU** Commission ruled that cannabidiol can be qualified as food, provided that also the other conditions of Article 2 of Regulation (EC) No178/2002 are met. Consequently, the Novel Foods application pathway is expected to be re-opened.
- **UK** Food Standards Agency (FSA) required that those looking to market ingestible CBD products will have to submit an application for Novel Foods to keep products on shelves beyond March 2021. Elixinol's EIHA application has been validated by the FSA and can remain in distribution whilst being reviewed.

Exploring fast developing Australian market:


- On 15 December 2020, Australia's Therapeutic Goods Administration (TGA) confirmed the de-scheduling of CBD from Schedule 4 to Schedule 3, thus enabling CBD products that are registered with the TGA to be widely distributed across pharmacies.



FY2020 financial summary

Well funded, reduced cost base and refocused on building a profitable consumer goods business.

Revenue by Channel
A\$ million, 31 December year end



Revenue by channel

Divested low margin business to focus on higher margin Elixinol branded products.

Driving margin improvement as business mix shifts towards branded consumer goods channels.

Annualised cost base

↓ 45%

Substantial operational and corporate cost reduction program completed in June 2020.

Well funded*


Cash reserves boosted by heavily oversubscribed capital raise provides new funding of \$20.5m.

↑ 37%

\$27.7m

Vs \$20.2m in FY2019

Adjusted EBITDA by Half
A\$ million, 31 December year end



Adjusted EBITDA**


Improved significantly between H1 and H2, despite lower revenues with a reduced cost base supporting a simplified strategy.

Cost reduction program and higher margin business driving performance improvements.



Q1 FY2021 update

Well funded, reduced cost base and refocused on building a profitable consumer goods business.



Revenue by month



Q1 FY2021 revenue of \$2.3m – 26% decline on previous quarter vs Q4 FY2020 of \$3.1m, reflecting normal seasonality, compounded by COVID-19 in key markets

Operating cash expenditure reduced

↓ 11%

Q1 FY2021¹ vs Q4 FY2020 following substantial operational and corporate costs reduction program


Well funded

\$23.3m

Cash on hand², \$3.6m cash used in operations¹ during Q1 FY2021 down from \$13.0m used in Q1 FY2020

Cash gross margin improvement

Driving margin improvement as business mix shifts towards branded consumer goods channels with focus on e-commerce.



Key highlights of Q1 FY2021

*The proposed CannaCare acquisition marked a material advance in our strategy to become a global consumer goods business. A strong funding position, improving margin profitability at a reduced cost base and the rekindling of UK trade conditions post **FSA Novel Foods Application validation** point towards a positive outlook.*



CannaCare SPA
Strategic EU market entry with #1 brand and outlook to improve Group revenue & profitability

Digital growth ↑
Continued e-commerce growth drives 36% of Group revenues with improving metrics across all regions

Strong funding position ↑
Cash reserves of \$23.3m boosted by heavily oversubscribed capital raising in Q4 FY2020

Margin accretion ↑
Group margin at highest level over recent 5 quarters as result of CPG and digital strategy

Tight cost controls ↓
Reduction in operating cash expenditure **down 11%** vs Q4 FY2020 substantial operational and corporate costs reduction program

UK: Superdrug launch & emerging from lock-downs
Full range launch in UK's **Superdrug** and start of replenishment orders post FSA NFA validation



ASX:EXL | OCTQB:ELLXF

Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business

15 March 2021



CannaCare overview

CannaCare presents an opportunity to take a significant share of Europe's fastest growing CBD market.

- Established 2018, based in Hamburg
- Extensive product range with 20 SKUs mainly consisting of oil, sprays and cosmetics marketed under CANOBO brand
- CANOBO #1 brand in German bricks and mortar retail with over 4,500 distribution points and an estimated market share of 42%¹ in the drugstore channel
- CANOBO first brand investing in broad reach media with several TV ads driving national consumer appeal
- Capital light model with outsourced supply chain
- Investment in new organic product certification
- Strict quality controls and independent testing regime



CannaCare distribution and routes-to-market

CannaCare enjoys a dominant position in traditional retail with particularly strong penetration in the drugstore channel (~42% market share ¹⁾) and pharmacies.

Pharmacy/Drugstores



Leading drugstore chain – 2,200 POS



Drugstores – 680 POS



Drugstores – 180 POS



1,500 Pharmacy distribution

E-Commerce



Major online retailer & publisher



Premium online cosmetics retailer



Premium online cosmetics retailer

Home Shopping



Leading European omnichannel retailer reaching ~45m German, Austrian and Swiss households

Supermarket



Leading German supermarket with over 50 stores

Online

Platform transitioning from Shopify to Magento in Q1 2021 to support growth and scalability

Key people

FRANK OTTO

Strategy Partner & Shareholder

Serial founder in the media industry

Founder and investor of many successful corporations (e.g. VIVA Music-Television)

Will join the Board of Elixinol Global as Non-Executive Director



OLIVER HAIST

Managing Director

L'Oréal – Group Key Account Manager FMCG

Philips – International Head of Sales FMCG

Leifheit – Export Director

Estée Lauder – Head of Sales and Marketing Germany



Transaction summary

Elixinol plans to acquire leading German-based CBD business, CannaCare, to accelerate its vision of becoming a global, hemp-derived health and wellness consumer products business.

Overview of CannaCare

- CannaCare's CANOBO brand is the leading company for premium CBD products in Germany's retail market (drugstores¹, pharmacies) with over 4,500 distribution points selling a range CBD oils, sprays and cosmetics
- Germany is 2nd largest and fastest growing CBD market in Europe. Estimated retail value in 2020 of US\$90m, expected to grow to US\$617m by 2025 (CAGR 47%)
- FY2020 revenue of €2.6m at break-even EBITDA (unaudited)
- 1st CBD brand to invest in extensive broad reach media and TV commercials
- Operating a capital light outsourced supply chain model similar to Elixinol UK
- Existing management team to remain in place. Major shareholder, Frank Otto, will join Elixinol's Board, bringing significant experience in the German and European markets

Purchase Consideration

- Up-front purchase price of €9m, comprising:
 - €3m cash; and
 - €6m of Elixinol scrip
- Up-front consideration implies 3.5x EV/revenue (LTM 31 December 2020) and 2.2x EV/revenue (based on annualised run-rate Q4 FY2020 revenue)
- Performance-based earn-out of up to €15.0m in Elixinol scrip, subject to achieving certain earn-out milestones

Earn-out Mechanism

- Maximum earn-out payable is €15.0m and CannaCare must achieve revenue during FY2021 of at least €6.5m for any earn-out to be payable (subject to a minimum EBITDA margin hurdle of 20%)
- Adjustment mechanism in place where FY2021 revenue achieved is greater than €6.5m but below minimum EBITDA threshold
- Earn-out to be paid in Elixinol scrip on or around 31 March 2022

Expected Financial Impact

- CannaCare delivered €2.6m of revenue in FY2020 with breakeven EBITDA and is expecting significant growth in FY2021
- At minimum threshold of €6.5m for an earn-out to be paid, CannaCare revenue would constitute +66% revenue growth on Elixinol Global's FY2020 audited revenue
- Acquisition expected to fast-track revenue growth and accelerate pathway to group profitability
- Substantial long-term synergy potential

Financial Implications

The following sets out some key effects to the Company as a result of the Proposed Transaction proceeding:

Scenario:

Upfront - cash (€3m)

Upfront - scrip (€6m)

Earn-out - scrip (between €0m-€15m)

Total Purchase Price (A\$m)

Nil earn-out ²	Max earn-out ⁴
4.6	4.6
9.2	9.2
-	<u>23.1</u>
13.9	36.9

¹ Elixinol Group financial statements for year ended 31 December 2020 (audited). Annual EBITDA excludes asset impairment expenses.

² CannaCare FY2020 are unaudited and are shown on a pro forma basis. Upfront consideration of €9m, with €6m to be paid in Elixinol shares (converted to AUD at 22 February 2020 EUR/AUD exchange rate of 1.5389). Shares are issued at Elixinol's 2 month VWAP prior to 22 February 2021 of A\$0.2105.

Scenario:

A\$m

Total Assets

Total Liabilities

Total Equity Interests

Total Securities on Issue (m)

Annual Revenue

Annual EBITDA

Before transaction	Increase/(decrease) due to transaction			
	Nil earn-out		Max earn-out	
Elixinol	CannCare			
FY2020 ¹	FY2020 ²	FY2021 ³	FY2020 ²	FY2021 ⁴
42.5	10.0	-	10.0	23.1
6.8	0.8	-	0.8	-
35.7	9.2	-	9.2	23.1
314.7	43.9	-	43.9	109.7
15.0	4.1	< 10.0	4.1	20.0
(22.9)	-	< 2.0	-	4.0

³ CannaCare FY2021 nil earn-out scenario shown where FY2021 revenue is <€6.5m @ minimum 20% EBITDA and therefore no earn-out is payable (converted to AUD at 22 February 2020 EUR/AUD exchange rate of 1.5389).

⁴ CannaCare FY2021 max earn-out scenario where FY2021 revenue is >€12.9m and minimum 20% EBITDA yielding a maximum potential earn-out of €15m payable as Elixinol shares which will be priced at 15 day VWAP prior to 31 March 2022 (for the purpose of this scenario, amounts shown assume an EUR/AUD exchange rate of 1.5389 and assumes 15 day VWAP prior to 31 March 2022 to be A\$0.2105).



Timetable

Event	Date
Despatch of Notice Of Meeting to shareholders (including Independent Expert's Report)	Thursday, 15 April 2021
Annual General Meeting	Monday, 17 May 2021
Targeted transaction completion	Monday, 5 July 2021
Issue of Upfront Consideration Shares	Monday, 5 July 2021
Issue of Earn-out Consideration Shares	Thursday, 31 March 2022
Upfront Consideration Shares released from voluntary escrow	Thursday, 31 March 2022

Takeaways

Broad hemp-based portfolio
including food,
skincare and
supplements

Trusted & established brand
with fresh
nutraceuticals
offering

Well positioned
in **high growth**
global CBD /
hemp
categories

Expanding global presence
with break-through
acquisition in
Germany

Optimised business model
with lower cost
and new
capabilities

Strong balance sheet with
\$23.3m of cash,
and virtually
debt free

**SUPPORTS HEALTHY
ANTIOXIDANT ACTIVITY**

450MG CBD PER BOTTLE





ASX:EXL | OCTQB:ELLXF



Q&A

<https://www.elixinolglobal.com/site/investor/investor-centre-home>



Kind of Amazing



For more information

Investor relations and media please contact:

Ron Dufficy, Global CFO
ron.dufficy@elixinolglobal.com